What type of study is this?

This is a Human Clinical Trial study.

What question did this study set out to answer?

This research aims to evaluate the effectiveness and safety of talquetamab in patients with relapsed refractory multiple myeloma in clinical practice.

December 8, 2025BloodOpen Access

Talquetamab outcomes from practice outside of clinical trials: The bital study

View Full Paper

Ask AI

Bookmark

This research aims to evaluate the effectiveness and safety of talquetamab in patients with relapsed refractory multiple myeloma in clinical practice.
Ongoing retrospective noninterventional study
Data collected from 68 sites across Spain
Evaluated treatment outcomes based on response rates, progression free survival, and overall survival
Subjects were patients treated with talquetamab who had triple-class exposure
Overall response rate was 83.8% with 65.4% achieving ≥VGPR
Median progression free survival was 8.6 months overall
Median overall survival was 26.2 months for the patient population
Adverse events included skin reactions in 75.5% and cytokine release syndrome in 55.2%

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

BiTAL study demonstrates effective treatment outcomes and safety of bispecific antibody talquetamab in relapsed refractory multiple myeloma.

Cite This Study

Arnao et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d16e https://doi.org/10.1182/blood-2025-5827

View Full Paper

Ask AI

Bookmark

Implication

BiTAL study demonstrates effective treatment outcomes and safety of bispecific antibody talquetamab in relapsed refractory multiple myeloma.

Talquetamab outcomes from practice outside of clinical trials: The bital study

Key Points

Discussion

Implication

Cite This Study

Talquetamab outcomes from practice outside of clinical trials: The bital study

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider